Radius Health Inc (NASDAQ:RDUS) was up 6.3% during mid-day trading on Tuesday following insider buying activity. The company traded as high as $21.89 and last traded at $21.47. Approximately 676,770 shares traded hands during mid-day trading, an increase of 14% from the average daily volume of 591,730 shares. The stock had previously closed at $20.19.
Specifically, Director Jessica Hopfield purchased 12,800 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was bought at an average cost of $19.23 per share, for a total transaction of $246,144.00. Following the purchase, the director now directly owns 12,800 shares in the company, valued at $246,144. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Debasish Roychowdhury sold 4,800 shares of the stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $22.15, for a total transaction of $106,320.00. Following the completion of the transaction, the director now owns 5,500 shares of the company’s stock, valued at $121,825. The disclosure for this sale can be found here. 4.00% of the stock is owned by company insiders.
Several research analysts recently issued reports on RDUS shares. BidaskClub lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Thursday, January 17th. HC Wainwright started coverage on shares of Radius Health in a research note on Thursday, February 14th. They set a “neutral” rating and a $22.00 price objective for the company. ValuEngine upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Finally, Cowen restated a “hold” rating on shares of Radius Health in a research note on Wednesday, May 8th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $38.00.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.32. The business had revenue of $34.42 million during the quarter, compared to analyst estimates of $33.99 million. Radius Health had a negative net margin of 176.84% and a negative return on equity of 191.58%. Equities analysts forecast that Radius Health Inc will post -3.62 EPS for the current year.
Several hedge funds have recently made changes to their positions in the company. BB Biotech AG grew its stake in shares of Radius Health by 1.8% in the fourth quarter. BB Biotech AG now owns 6,710,276 shares of the biopharmaceutical company’s stock worth $110,652,000 after acquiring an additional 120,000 shares during the period. Vanguard Group Inc grew its stake in shares of Radius Health by 1.5% in the third quarter. Vanguard Group Inc now owns 3,571,571 shares of the biopharmaceutical company’s stock worth $63,574,000 after acquiring an additional 53,281 shares during the period. Vanguard Group Inc. grew its stake in shares of Radius Health by 1.5% in the third quarter. Vanguard Group Inc. now owns 3,571,571 shares of the biopharmaceutical company’s stock worth $63,574,000 after acquiring an additional 53,281 shares during the period. Artisan Partners Limited Partnership grew its stake in shares of Radius Health by 1.1% in the first quarter. Artisan Partners Limited Partnership now owns 705,574 shares of the biopharmaceutical company’s stock worth $14,069,000 after acquiring an additional 7,872 shares during the period. Finally, Spark Investment Management LLC grew its stake in shares of Radius Health by 15.5% in the first quarter. Spark Investment Management LLC now owns 677,800 shares of the biopharmaceutical company’s stock worth $13,515,000 after acquiring an additional 91,200 shares during the period.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/15/radius-health-rdus-trading-up-6-3-after-insider-buying-activity.html.
About Radius Health (NASDAQ:RDUS)
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Featured Article: Determine Your Level of Risk Tolerance
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.